# CATB-101

Source: https://onco.cc/drugs/catb-101/  
OnCo record `catb-101` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CATB-101 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.

## Summary

CatenaBio describes CATB-101 in AACR 2026 abstract 6928. The two payloads inhibit topoisomerase I and tubulin. Cell-derived and patient-derived xenografts and non-GLP monkey studies are preclinical evidence; they do not demonstrate efficacy or a safer therapeutic window in patients. The abstract supports development, without a human response or survival readout.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-10-06
- Tags: evidence:preclinical
- Modality: ADC
- Mechanism: Dual-payload anti-TROP2 antibody-drug conjugate delivering inhibitors of DNA processing and microtubule function.
- Payload: TOP1 inhibitor plus tubulin inhibitor

## Sources

- Publisher abstract: https://doi.org/10.1158/1538-7445.am2026-6928

## Connected records

- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Dual-payload ADC](https://onco.cc/technologies/dual-payload-adc/)
- targets: [TROP2](https://onco.cc/targets/trop2/)

---
JSON: https://onco.cc/api/v1/entities/catb-101.json